9:25 AM ET
8-K
Regulatory Approval
Edesa Biotech Regulatory Approval
Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.
- Counterparty
- European Commission
- Term
- 10 years